Drugs / recombinant fowlpox-prostate specific antigen vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00045227 | Aug 2002 → Oct 2007 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005916 | Jun 2000 → Dec 2005 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00020254 | Jun 2000 → Oct 2004 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005039 | Jan 2000 → Mar 2007 | prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-prostate specific antigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005039 ↗ |
| Known as | rF-PSA | “sequential booster vaccinations with recombinant fowlpox virus (rF-) containing the PSA gene (rF-PSA).” PMID 16489082 ↗ Feb 2006 |
| Action | Deplete | “Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells” NCT00005039 ↗ |
| Modality | Vaccine | “recombinant fowlpox-PSA vaccine” NCT00005039 ↗ |
| Route | Intramuscular | “Given IM” NCT00005039 ↗ |